hotspot -WSS

hotspot

author：hotspot 2025-10-01 00:49:34 - browse：79767

Tortoise and hare — Medical devices have historically been seen as having faster paths to market than their pharmacological counterparts. The growing requirement for cost-effectiveness trials may be slowing them down. Jonathan Elderfield/AP

When a colleague and I started our medical device company in 2009, we were in our second year at Harvard Medical School. Some classmates joked that they would still be in residency by the time we had moved on to our next big idea. We knew better — we expected it to be a long haul. Eight years into our journey, thousands of individuals have used our product in countries where it has been approved. But we have yet to gain approval in the U.S. — a long and expensive process.

In 2016, the United States Food and Drug Administration approved 22 new drugs, down from 45 approvals in 2015. The decline in drug discovery has been attributed to a variety of factors that include ballooning research and development expenses (the cost to develop a new drug is now estimated to be more than $2.5 billion), high rates of failure (a whopping 90 percent of Phase 1 candidates never make it to launch), and the complexity of human biology, which can thwart even the most promising candidates.

Medical devices have historically been viewed as having faster and lower-cost paths to market than their pharmacological counterparts: the average cost to develop high-risk, novel medical devices is estimated to be $94 million. After all, device engineers can leverage lower-cost animal models further into development than their pharmaceutical colleagues, the human clinical trials necessary for FDA approval are often smaller in scale, and, in some cases, expenses can be defrayed by revenue generated outside the United States in markets with faster regulatory pathways.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： My superpower is killing ticks

leisure time

WSS

Report: NIH

Scientists successfully use ultrasound imaging to map brain activity

'Ancient DNA,' 23andMe reveal African American ancestries

Who is Magistrate Judge Moxila Upadhyaya in Trump's Jan. 6 case?

Report: NIH

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

hotspot

hotspot

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

First Opinion Podcast: What happens when kids become caregivers?

State Dept. review finds Biden bears some blame for Afghanistan failures

What the cancer research community can learn from the Covid response

Heart attack and stroke risk calculators need revising

Prosthetic arm enables patients to feel the objects they grip

Novavax promises a turnaround & Lilly roils the obesity market

Nearly two

In Memoriam: Notable people who died in 2023

Adam's Biotech Scorecard: Do Sarepta's exon

leisure time

For BCIs, commercial hurdles may be bigger than scientific ones

Scientists successfully use ultrasound imaging to map brain activity

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

What will save rural psychiatry services? Higher Medicaid payments

Health insurers say they are turning to AI to cut costs, improve care

OTC birth control: A brief history of over the counter pill design

focus

focus

leisure time

focus